Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients
Nephrology Dialysis Transplantation · 27.03.2024 · 39 (4) · 618-626
DOI: 10.1093/ndt/gfad190 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 02.09.2023. Verfasst von Pedro Barrera-Baena und 21 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Bone and Mineral Research Unit, REDinREN and RICORS2040 del ISCIII, Oviedo, S…. Hauptthemen laut MEDLINE: Renal Dialysis, Phosphates, Fractures, Bone. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Instituto de Salud Carlos III, European Commission, Tecnología e Innovación.
Abstract (Originalsprache)
Background
Bone fragility fractures are associated with high morbidity and mortality. This study analysed the association between the current biochemical parameters of chronic kidney disease–mineral and bone disorders (CKD-MBD) and bone fragility fractures in the COSMOS (Current management Of Secondary hyperparathyroidism: a Multicentre Observational Study) project.
Methods
COSMOS is a 3-year, multicentre, open cohort, prospective, observational study carried out in 6797 haemodialysis patients (227 centres from 20 European countries). The association of bone fragility fractures (outcome) with serum calcium, phosphate and parathyroid hormone (PTH) (exposure), was assessed using standard Cox proportional hazards regression and Cox proportional hazards regression for recurrent events. Additional analyses were performed considering all-cause mortality as a competitive event for bone fragility fracture occurrence. Multivariable models were used in all strategies, with the fully adjusted model including a total of 24 variables.
Results
During a median follow-up of 24 months, 252 (4%) patients experienced at least one bone fragility fracture (incident bone fragility fracture rate 28.5 per 1000 patient-years). In the fractured and non-fractured patients, the percentage of men was 43.7% and 61.4%, mean age 68.1 and 63.8 years and a haemodialysis vintage of 55.9 and 38.3 months, respectively. Baseline serum phosphate >6.1 mg/dL (reference value 4.3–6.1 mg/dL) was significantly associated with a higher bone fragility fracture risk in both regression models {hazard ratio (HR) 1.53 [95% confidence interval (CI) 1.10–2.13] and HR 1.44 (95% CI 1.02–2.05)}. The significant association persisted after competitive risk analysis [subHR 1.42 (95% CI 1.02–1.98)] but the finding was not confirmed when serum phosphate was considered as a continuous variable. Baseline serum calcium showed no association with bone fragility fracture risk in any regression model. Baseline serum PTH >800 pg/mL was significantly associated with a higher bone fragility fracture risk in both regression models, but the association disappeared after a competitive risk analysis.
Conclusions
Hyperphosphatemia was independently and consistently associated with an increased bone fracture risk, suggesting serum phosphate could be a novel risk factor for bone fractures in haemodialysis patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Bone and Mineral Research Unit, REDinREN and RICORS2040 del ISCIII, Oviedo, Spain.
- Hospital Universitario de Cabueñes, Department of Nephrology, Gijón, Spain.
- Hospital Universitario Central de Asturias, Department of Nephrology, REDinREN del ISCIII, Oviedo, Spain.
- IIS-Fundacion Jimenez Diaz UAM, Department of Nephrology and Hypertension, Madrid, Spain.
- RICORS2040; Madrid, Spain.
- Universidad Autónoma de Madrid, Facultad de Medicina, Departamento de Medicina, Madrid, Spain.
ORCID-Profile: Pedro Barrera-Baena, Alberto Ortiz, Carmine Zoccali, Francesco Locatelli, José Luis Gorriz-Teruel, Emilio Sánchez-Álvarez, Beatriz Martín-Carro, Cristina Alonso-Montes, José Luis Fernández-Martín
Förderung
- Instituto de Salud Carlos III
- European Commission
- Tecnología e Innovación
- Hospital Universitario Central de Asturias
- Sociedad Asturiana Fomento Investigaciones Óseas
- European Renal Association
- FRIAT
- Spanish Society of Nephrology
Zitieren
APA
Barrera-Baena, P., Rodríguez-García, M., Rodríguez-Rubio, E., González-Llorente, L., Ortiz, A., Zoccali, C., Locatelli, F., Floege, J., Cohen-Solal, M., Ferreira, M. A., Ketteler, M., London, G. M., Gorriz-Teruel, J. L., Sánchez-Álvarez, E., Hevia-Suárez, M. Á., Fernández-Gómez, J. M., Martín-Carro, B., Gómez-Alonso, C., Alonso-Montes, C., …, & COSMOS (2024). Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients. Nephrology Dialysis Transplantation, 39(4), 618-626. https://doi.org/10.1093/ndt/gfad190
Vancouver
Barrera-Baena P, Rodríguez-García M, Rodríguez-Rubio E, González-Llorente L, Ortiz A, Zoccali C, et al. Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients. Nephrology Dialysis Transplantation. 2024;39(4):618-626. doi:10.1093/ndt/gfad190
BibTeX
@article{BarreraBaena2024,
author = {Barrera-Baena, Pedro and Rodríguez-García, Minerva and Rodríguez-Rubio, Enrique and González-Llorente, Lucía and Ortiz, Alberto and Zoccali, Carmine and Locatelli, Francesco and Floege, Jürgen and Cohen-Solal, Martine and Ferreira, Manuel Aníbal and Ketteler, Markus and London, Gerard Michel and Gorriz-Teruel, José Luis and Sánchez-Álvarez, Emilio and Hevia-Suárez, Miguel Ángel and Fernández-Gómez, Jesús María and Martín-Carro, Beatriz and Gómez-Alonso, Carlos and Alonso-Montes, Cristina and Cannata-Andía, Jorge Benito and Fernández-Martín, José Luis and COSMOS, COSMOS},
title = {Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients},
journal = {Nephrology Dialysis Transplantation},
year = {2024},
volume = {39},
number = {4},
pages = {618--626},
doi = {10.1093/ndt/gfad190}
}
EUVIMED